BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11032566)

  • 1. Nonalcoholic fatty liver disease is associated with hyperlipidemia and obesity.
    Sharabi Y; Eldad A
    Am J Med; 2000 Aug; 109(2):171. PubMed ID: 11032566
    [No Abstract]   [Full Text] [Related]  

  • 2. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy.
    Shieh K; Gilchrist JM; Promrat K
    Muscle Nerve; 2010 Feb; 41(2):197-201. PubMed ID: 19813185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabesity: the deadly pentad disease.
    Daly A
    Diabetes Educ; 1994; 20(2):156-8, 160-2. PubMed ID: 7851230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes and the heart.
    Scott RC
    Am Heart J; 1975 Sep; 90(3):283-9. PubMed ID: 1099885
    [No Abstract]   [Full Text] [Related]  

  • 5. [Recent topics on nonalcoholic steatohepatitis].
    Saibara T; Onishi S; enzan H
    Nihon Naika Gakkai Zasshi; 2003 Jun; 92(6):1104-9. PubMed ID: 12866461
    [No Abstract]   [Full Text] [Related]  

  • 6. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
    van Heek M; Austin TM; Farley C; Cook JA; Tetzloff GG; Davis HR
    Diabetes; 2001 Jun; 50(6):1330-5. PubMed ID: 11375333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk factors for coronary heart disease in 1002 patients with hyperlipidemia].
    Kłosiewicz-Latoszek L; Pachocka L; Górska K; Grzybowska B; Ostasz B; Paluszkiewicz J; Szonert J; Targosz U; Stolarska I; Nowicka G
    Pol Arch Med Wewn; 1997 May; 97(5):442-9. PubMed ID: 9411422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary and physical activity patterns in children with fatty liver.
    Mager DR; Patterson C; So S; Rogenstein CD; Wykes LJ; Roberts EA
    Eur J Clin Nutr; 2010 Jun; 64(6):628-35. PubMed ID: 20216561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome and its association with colorectal cancer: a review.
    Siddiqui AA
    Am J Med Sci; 2011 Mar; 341(3):227-31. PubMed ID: 20460980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity, islet function and diabetes mellitus.
    Pfeifer EF
    Horm Metab Res; 1974; Suppl 4():143-52. PubMed ID: 4608433
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel?
    Hopkins PN; Hunt SC; Wu LL; Williams GH; Williams RR
    Curr Opin Lipidol; 1996 Aug; 7(4):241-53. PubMed ID: 8883500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of obesity in primary hyperlipidemias.
    Carmena R; Ascaso JF; Real JT
    Nutr Metab Cardiovasc Dis; 2001 Oct; 11(5):354-9. PubMed ID: 11887432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia of central obesity and insulin resistance.
    Brunzell JD; Hokanson JE
    Diabetes Care; 1999 Apr; 22 Suppl 3():C10-3. PubMed ID: 10189557
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonalcoholic steatohepatitis: a review of the literature and updates in management.
    Pasumarthy L; Srour J
    South Med J; 2010 Jun; 103(6):547-50. PubMed ID: 20710138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mode of action of benfluorex. Recent data].
    Brindley DN
    Presse Med; 1992 Sep; 21(28):1330-5. PubMed ID: 1438102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of obesity and glucose-stimulated insulin secretion in familial hypertriglyceridemia.
    Maruhama Y; Abe R; Okuguchi F; Oikawa S; Ohneda A; Goto Y
    Diabetes; 1978 Jun; 27(6):682-93. PubMed ID: 658614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of nonalcoholic fatty liver disease.
    Angulo P
    Ann Hepatol; 2002; 1(1):12-9. PubMed ID: 15114291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of serum C3 complement with insulin resistance and coronary heart disease-cause, consequence or common antecedent?
    Yudkin JS
    Eur Heart J; 2000 Jul; 21(13):1036-9. PubMed ID: 10843818
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural history of nonalcoholic fatty liver disease: insights from children and mice.
    Ahima RS
    Gastroenterology; 2008 Dec; 135(6):1860-2. PubMed ID: 19000676
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.